CD8A and hepatocellular carcinoma: In line with these preclinical data, the majority of evaluable patients (11/15) with hepatocellular carcinoma (HCC) treated with intratumoral injections of ilixadencel [14] showed an increased frequency of interferon-gamma–producing CD8+ T cells specific for the HCC-associated tumor antigens hTERT and/or AFP.